Clinical trials: Hemostatic Disorders
Epistaxis
Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis
Purpose: This study is a prospective clinical trial to investigate the efficacy of a chitosan-coated nasal packing (ChitoFlex® used in conjunction with the HemCon Nasal Plug) in the management of difficult spontaneous epistaxis…
- Trial name
- NCT00863356
- Testing
- 2009-I-Epistaxis-1
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- HemCon Medical Technologies, Inc
Congenital Heart Disease, Unfractionated Heparin
Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)
This study aims to compare the accuracy of two different blood sampling methods from a central venous catheter (CVC) for measuring anti-Xa activity in children receiving unfractionated heparin (UFH) from this CVC.
- Conditions
- Congenital Heart Disease, Unfractionated Heparin, Anti Xa Activity
- Trial name
- COMPAXE-HNF (NCT07365670)
- Testing
- blood sampling for measuring anti-Xa activity, measurement of anti-XA activity
- Volunteers
- 22 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Multiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- NCT05372354
- Testing
- CC-92480, Tazemetostat, BMS-986158
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Drugs used in chemotherapy such as FR901228 use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of FR901228 in treating patients who have relapsed or…
- Conditions
- DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT00066638
- Testing
- Romidepsin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT01075321
- Testing
- everolimus, lenalidomide, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who…
- Trial name
- KarMMa-2 (NCT03601078)
- Testing
- bb2121, Lenalomide, Talquetamab
- Where
- 25 sites in United States, France and 4 more
- Volunteers
- 312 people
- Sponsor
- Celgene
Multiple Myeloma
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
Multiple myeloma (MM) is a malignant proliferative plasma cell disease, which accounts for approximately 10% and ranks secondly of hematological malignancies in many countries.
- Trial name
- NCT06039735
- Testing
- Chemotherapy and/or autologous hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Hospital of Shandong University
Multiple Myeloma
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
The trial is a single-center, single-arm, prospective clinical study with a planned enrollment of 15 patients with primary Multiple myeloma(MM), aiming to investigate the efficacy and safety of maintenance therapy with…
- Trial name
- NCT05378971
- Testing
- Pomalidomide
- Where
- China
- Volunteers
- 15 people
- Sponsor
- LanZhou University
Breast Cancer, Colorectal Cancer
SU006668 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs such as SU006668 may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU006668 in treating patients who have advanced solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer
- Trial name
- NCT00024063
- Testing
- orantinib
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
This is a pilot feasibility trial among older adults (≥60y) scheduled to undergo Autologous Stem Cell transplantation at UAB. Participants will be randomized into either a prehabilitation program or an attention control group…
- Trial name
- NCT05642884
- Testing
- Multi-modal Exercise Regimen, Dietary Guidelines
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Noha Mohamed Sharafeldin
Multiple Myeloma
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who…
- Trial name
- KarMMa-9 (NCT06045806)
- Testing
- idecabtagene vicleucel, Lenalidomide, Fludarabine
- Where
- 101 sites in United States, Australia and 16 more
- Volunteers
- 79 people
- Sponsor
- Celgene
Multiple Myeloma
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple…
- Trial name
- NCT06048250
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Hypermobility Syndrome, Danlos Disease, Ehlers
Functional Instability in Patients Suffering From Collagen Disease and Joint Hypermobility
A joint is considered "hypermobile" when it has a greater range of motion than normal for a given age, ethnicity or gender. Many people have asymptomatic hyperlaxity in multiple joints, a condition called Generalized Joint…
- Conditions
- Hypermobility Syndrome, Danlos Disease, Ehlers, Collagen Diseases, Joint Hypermobility
- Trial name
- VIPIA (NCT05871216)
- Testing
- Clinical tests and balance evaluation using the Delos Proprioceptive System
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Istituto Ortopedico Rizzoli
Multiple Myeloma
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
- Trial name
- NCT00103506
- Testing
- Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 646 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003143
- Testing
- Amifostine, DHAP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with…
- Trial name
- NCT01456689
- Testing
- LGH447, midazolam
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma or Amyloidosis
Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System
This study is evaluating a new method for administering daratumumab, a treatment commonly used in the management of multiple myeloma and amyloidosis.
- Trial name
- ESCAPE (NCT07721350)
- Testing
- Subcutaneous Daratumumab Administration Using FreedomEDGE®
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
This is a single-arm, open-label study evaluating the safety, tolerability and efficacy of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in patients with RRMM.
- Trial name
- CC-220 (NCT05560399)
- Testing
- Iberdomide, Elotuzumab, Dexamethasone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This study is a single-center, open-label, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or Plasma Cell Leukemia.
- Trial name
- NCT05759793
- Testing
- CAR-GPRC5D
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Myeloma Multiple
Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma
Multiple myeloma (MM) survival has been improved during the last decade owing to new treatments. Hence, it has become a matter of importance to precisely define the depth of MM response to therapy.
- Trial name
- MYELOCHOL (NCT03891914)
- Testing
- Positron Emission Tomography using 18F-FCH, Positron Emission Tomography using 18F-FDG
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.